PURPOSE: To compare self-reported quality of life (QOL) in patients who did versus did not undergo interval secondary cytoreduction after initial surgery and combination chemotherapy for advanced ovarian cancer and to assess the association between baseline QOL scores and survival. PATIENTS AND METHODS: Consenting patients participating in a Gynecologic Oncology Group (GOG) phase III treatment trial (GOG 152) completed theFunctional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaire and treatment-specific supplemental questions at the third and sixth chemotherapy cycles and at 6 and 12 months after starting treatment. RESULTS: For all patients, QOL decreased approximately 1 unit from the first to second assessment. Significant improvement observed at 6 months (P < .001) was sustained at 12 months, with no appreciable between-group difference. The baseline FACT-O score was associated with overall survival (P = .048) but not progression-free survival. Less neurotoxicity was reported among patients who did (38.4%) versus did not (54.0%) undergo interval secondary cytoreduction at the third assessment (P = .005), and older patients experienced more long-term effects. CONCLUSION: This is the first multicenter randomized trial in ovarian cancer to longitudinally examine self-reported QOL and establish a predictive value of baseline QOL on survival, attributed primarily to the lowest-scoring quartile. Although interval secondary cytoreduction resulted in no notable long-term difference, a clinically significant improvement was seen in both arms at 6 and 12 months after starting therapy. Interestingly, there were fewer complaints of neurotoxicity at 6 months among patients who did versus did not undergo interval secondary cytoreduction.
RCT Entities:
PURPOSE: To compare self-reported quality of life (QOL) in patients who did versus did not undergo interval secondary cytoreduction after initial surgery and combination chemotherapy for advanced ovarian cancer and to assess the association between baseline QOL scores and survival. PATIENTS AND METHODS: Consenting patients participating in a Gynecologic Oncology Group (GOG) phase III treatment trial (GOG 152) completed the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaire and treatment-specific supplemental questions at the third and sixth chemotherapy cycles and at 6 and 12 months after starting treatment. RESULTS: For all patients, QOL decreased approximately 1 unit from the first to second assessment. Significant improvement observed at 6 months (P < .001) was sustained at 12 months, with no appreciable between-group difference. The baseline FACT-O score was associated with overall survival (P = .048) but not progression-free survival. Less neurotoxicity was reported among patients who did (38.4%) versus did not (54.0%) undergo interval secondary cytoreduction at the third assessment (P = .005), and older patients experienced more long-term effects. CONCLUSION: This is the first multicenter randomized trial in ovarian cancer to longitudinally examine self-reported QOL and establish a predictive value of baseline QOL on survival, attributed primarily to the lowest-scoring quartile. Although interval secondary cytoreduction resulted in no notable long-term difference, a clinically significant improvement was seen in both arms at 6 and 12 months after starting therapy. Interestingly, there were fewer complaints of neurotoxicity at 6 months among patients who did versus did not undergo interval secondary cytoreduction.
Authors: Peter G Rose; Stacy Nerenstone; Mark F Brady; Daniel Clarke-Pearson; George Olt; Stephen C Rubin; David H Moore; James M Small Journal: N Engl J Med Date: 2004-12-09 Impact factor: 91.245
Authors: M E van der Burg; M van Lent; M Buyse; A Kobierska; N Colombo; G Favalli; A J Lacave; M Nardi; J Renard; S Pecorelli Journal: N Engl J Med Date: 1995-03-09 Impact factor: 91.245
Authors: K Basen-Engquist; D Bodurka-Bevers; M A Fitzgerald; K Webster; D Cella; S Hu; D M Gershenson Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: David Cella; David T Eton; Diane L Fairclough; Philip Bonomi; Anne E Heyes; Cheryl Silberman; Michael K Wolf; David H Johnson Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437
Authors: A B Kornblith; H T Thaler; G Wong; V Vlamis; J M Lepore; D B Loseth; T Hakes; W J Hoskins; R K Portenoy Journal: Gynecol Oncol Date: 1995-11 Impact factor: 5.482
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Sally E Jensen; Sarah K Rosenbloom; Jennifer L Beaumont; Amy Abernethy; Paul B Jacobsen; Karen Syrjala; David Cella Journal: Gynecol Oncol Date: 2010-11-13 Impact factor: 5.482
Authors: Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Gibbons; Bradley J Monk; Peter G Rose; Deborah K Armstrong; David Cella; Lari Wenzel Journal: J Pain Symptom Manage Date: 2010-05 Impact factor: 3.612
Authors: Kemi M Doll; Alison K Kalinowski; Anna C Snavely; Debra E Irwin; Jeannette T Bensen; Victoria L Bae-Jump; Kenneth H Kim; Linda Van Le; Daniel L Clarke-Pearson; Paola A Gehrig Journal: Cancer Date: 2014-09-23 Impact factor: 6.860
Authors: Dominique Koensgen; Guelten Oskay-Oezcelik; Ioanna Katsares; Ulla Walle; Christine Klapp; Alexander Mustea; Dirk Stengel; Franz Porzsolt; Werner Lichtenegger; Jalid Sehouli Journal: Support Care Cancer Date: 2009-09-17 Impact factor: 3.603